Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2014
05/01/2014WO2014064149A1 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors
05/01/2014WO2014064134A1 3,4-disubstituted 1 h-pyrazole and 4,5-disubstituted thiazole inhibitors of syk
05/01/2014WO2014063778A1 2-aminopyridine compounds
05/01/2014WO2014063659A1 Treatment of cancer using a smad3 inhibitor
05/01/2014WO2014063631A1 Tyrosine kinase irreversible inhibitor and preparation method and applications thereof
05/01/2014WO2014063601A1 Vaccine for inducing specific immunity of tumor and application thereof
05/01/2014WO2014063549A1 Amphiphilic block copolymer and preparation method thereof and micellar drug-loading system formed by same with antitumor drug
05/01/2014WO2014063495A1 Rtrail mutant and monomethyl auristatin e conjugate thereof
05/01/2014WO2014063368A1 Humanized monoclonal antibody in extracellular domain of anti-human death receptor 5
05/01/2014WO2014063205A1 Use of endocytosis inhibitors and antibodies for cancer therapy
05/01/2014WO2014063199A1 Organic compounds
05/01/2014WO2014037834A3 Compositions and methods for treatment of inflammation and lipid disorders
05/01/2014WO2014037588A3 Methods and compounds for preventing, treating and diagnosing an inflammatory condition
05/01/2014WO2014035140A3 Compounds and compositions for modulating histone methyltransferase activity
05/01/2014WO2014031732A3 Methods for inhibiting fascin
05/01/2014WO2014015153A3 Treating ewing's sarcoma and ews-fli1 related disorders
05/01/2014WO2014004934A3 Compositions and methods of treating alzheimer's disease
05/01/2014WO2013188391A3 Biomarkers for ovarian cancer
05/01/2014WO2013186793A9 Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells
05/01/2014US20140121278 Anti-tumor agent otx-008 targets human galectin-1
05/01/2014US20140121228 Quinazoline Derivatives as VEGF Inhibitors
05/01/2014US20140121169 Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
05/01/2014US20140120089 Antibodies to insulin-like growth factor i receptor
05/01/2014CA2805093A1 Anti-tumor agent otx-008 targets human galectin-1
04/2014
04/30/2014EP2725100A1 Method for amplifying nk cells
04/30/2014EP2725013A1 Novel histone deacetylase inhibitor of benzamides and use thereof
04/30/2014EP2724729A1 Apoptosis-inducing agent
04/30/2014EP2724156A1 Methods and compositions for treatment of cancer and autoimmune disease
04/30/2014EP2723862A1 Albumin production and cell proliferation
04/30/2014EP2723748A1 Heterocyclyl aminoimidazopyridazines
04/30/2014EP2723747A1 Compounds useful as inhibitors of atr kinase
04/30/2014EP2723746A1 Compounds useful as inhibitors of atr kinase
04/30/2014EP2723745A1 Compounds useful as inhibitors of atr kinase
04/30/2014EP2723741A2 Substituted imidazopyridinyl-aminopyridine compounds
04/30/2014EP2723739A1 Substituted 6-aza-isoindolin-1-one derivatives
04/30/2014EP2723736A1 7-azaindole derivatives suitable for treatment of cancers
04/30/2014EP2723733A1 Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
04/30/2014EP2723731A1 Metalloenzyme inhibitor compounds
04/30/2014EP2723450A2 Combination therapy
04/30/2014EP2723449A2 Compounds for the treatment of cancers associated with human papillomavirus
04/30/2014EP2723389A2 Novel maytansinoid derivatives with peptide linker and conjugates thereof
04/30/2014EP2723388A1 Controlled release system
04/30/2014EP2723387A1 Cathepsin-binding compounds bound to a carrier and their diagnostic use
04/30/2014EP2723381A2 Focused radiation for augmenting immune-based therapies against neoplasms
04/30/2014EP2723350A1 New uses of nanog inhibitors and related methods
04/30/2014EP2723345A2 Composition comprising phosphatidylcholine as an active ingredient for attenuating toxicity of anticancer agent
04/30/2014EP2723340A1 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
04/30/2014EP2723333A1 Treatment and prevention of diseases related to oxidative stress
04/30/2014EP2723328A1 Combination treatment comprising a hdac6 inhibitor and an akt inhibitor
04/30/2014EP2723324A1 Compositions and methods for the treatment of cancer
04/30/2014EP2723196A1 Wheat germ extract obtained by protease hydrolysis and medical use thereof
04/30/2014CN103765212A Methods and compositions for treatment of cancer and autoimmune disease
04/30/2014CN103764847A Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
04/30/2014CN103764830A Composition comprising inhibitors of IRS-1 and of VEGF
04/30/2014CN103764825A Cancer treatment and/or prevention drug composition
04/30/2014CN103764681A Bispecific antigen binding molecules
04/30/2014CN103764678A c-Met antibody combinations
04/30/2014CN103764676A Fusion gene of KIF5B gene and RET gene, and method for determining effectiveness of cancer treatment targeting fusion gene
04/30/2014CN103764668A Leukemia stem cell targeting ligands and methods of use
04/30/2014CN103764667A N-carboxyalkyl-auristatins and use therof
04/30/2014CN103764659A Glioblastoma inhibiting compounds and their use
04/30/2014CN103764658A Compounds, their pharmaceutical compositions and their uses as IDH1 mutants inhibitors for treating cancers
04/30/2014CN103764656A Heterocyclyl aminoimidazopyridazines
04/30/2014CN103764651A 7-azaindole derivatives suitable for treatment of cancers
04/30/2014CN103764647A Metalloenzyme inhibitor compounds
04/30/2014CN103764646A Metalloenzyme inhibitor compounds
04/30/2014CN103764637A Solid state forms of cabazitaxel and processes for preparation thereof
04/30/2014CN103764619A Tetravalent platinum complex and pharmaceutical composition containing same
04/30/2014CN103764604A Stilbene analogs and methods of treating cancer
04/30/2014CN103764172A Controlled release system
04/30/2014CN103764170A Novel binder-drug conjugates (ADCs) and their use
04/30/2014CN103764165A Drug for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor GC-A agonist and GC-B agonist
04/30/2014CN103764161A Anti-cancer composition comprising Wnt decoy receptors
04/30/2014CN103764152A Anti-tumor agent
04/30/2014CN103764144A Synergistic combinations of pi3k- and mek-inhibitors
04/30/2014CN103764143A Lipoxygenase inhibitors
04/30/2014CN103764142A Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
04/30/2014CN103764139A Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset
04/30/2014CN103764137A Eosinophil peroxidase compositions and methods of their use
04/30/2014CN103764130A Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone
04/30/2014CN103757022A Interfering RNA (ribonucleic acid) molecule and application thereof
04/30/2014CN103757021A Double-chain siRNA molecule of silencing DNMT (Desoxvribose Nucleic Acid Methyltransferases) gene and application of double-chain siRNA molecule
04/30/2014CN103756916A Acremonium terricola mutant strain and application thereof
04/30/2014CN103755888A Amphiphilic polymer and preparation thereof as well as magnetic hollow nano-drug carrier and preparation method thereof
04/30/2014CN103755828A Ganoderma lucidum spore polysaccharide and preparation method and application thereof
04/30/2014CN103755814A TAT-IL-24-KDEL fusion protein as well as preparation method and application thereof
04/30/2014CN103755813A Targeting anti-tumor fusion protein, and encoding gene and expression plasmid thereof
04/30/2014CN103755812A GM-CSF-HER2 recombinant protein, and preparation method and applications thereof
04/30/2014CN103755811A AFP recombinant protein, and in vitro high-efficiency recombination expression method
04/30/2014CN103755809A Antibodies for treating and diagnosing tumors expressing SLC34A2(TAT211=SEQID2)
04/30/2014CN103755808A Novel anti-alpha5beta1 antibodies and uses thereof
04/30/2014CN103755807A Specific binding agents to hepatocyte growth factor
04/30/2014CN103755805A Human monoclonal antibody with HIV-1 Env specificity
04/30/2014CN103755801A Application of combination of earthworm fibrinolytic-activity protein and paclitaxel in preparing drugs for inhibiting cancer cells
04/30/2014CN103755799A Tumstatin No.30 peptide having anti-tumor effect, and preparation method and application thereof
04/30/2014CN103755798A Bufo gargarizans antimicrobial peptide BG-SK14, and coding gene and application thereof
04/30/2014CN103755797A Antimicrobial peptide BG-CATH6 (5-29) of Bufo bufo gargarizans as well as encoding genes and application of antimicrobial peptide BG-CATH6 (5-29) of Bufo bufo gargarizans
04/30/2014CN103755796A Amolops Hainan ensis anticancer peptides Hainanenin-1 as well as gene and application thereof
04/30/2014CN103755789A Regulatory T cell epitopes, compositions and uses thereof
04/30/2014CN103755780A Active polypeptide separation and extraction process
1 ... 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 ... 2211